SequelSEC

Edesa Biotech, Inc. EDSA

Pharmaceutical Preparations · CIK 0001540159 · Fiscal year ends 0930

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2021-09-30
Operating income
-$5.48M
Fiscal year ended 2021-09-30
Free cash flow
Unavailable
Fiscal year ended 2021-09-30

Edesa Biotech, Inc. (EDSA) reported revenue of $0 and net income of -$3.69M for the fiscal year ended 2021-09-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Edesa Biotech, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Edesa Biotech, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-06-302019-03-31
Revenue$0$0$0$0$500$109.98K$110.52K$107.80KUnavailable$0
Cost of revenue$0$0$0$0$2.31K$1.47K$10.04K$3.78KUnavailable$0
Gross profit$0$0$0$0-$1.81K$108.51K$100.48K$104.02KUnavailable$0
Operating income-$5.48M-$6.07M-$9.51M-$2.61M-$2.01M-$1.77M-$1.52M-$1.11MUnavailable-$540.78K
Net income-$3.69M-$4.76M-$2.26M-$2.64M-$2.01M-$1.77M-$1.49M-$1.09MUnavailable-$528.83K
Research & development$4.13M$4.46M$7.98M$1.38M$1.15M$1.14M$502.81K$528.00KUnavailable$111.70K
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$3.69M-$4.76M-$2.26MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$1.66M
Income tax expense$0$0$800$0$0$0$0$800Unavailable$0
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$1.36M$1.61M$1.54M$1.23M$853.89K$733.08K$1.11M$681.71KUnavailable$429.08K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Edesa Biotech, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-06-302019-03-31
Cash & equivalents$7.84M$8.05M$10.97M$6.31M$7.21M$5.64M$6.99M$3.83MUnavailable$3.04M
Total assets$14.58M$16.88M$24.00M$10.29M$10.76M$8.92M$7.63M$5.09MUnavailable$9.15M
Current assets$12.09M$14.33M$21.42M$7.67M$8.10M$6.22M$7.43M$4.83MUnavailable$8.14M
Total liabilities$1.53M$1.07M$4.73M$1.03M$1.65M$1.12M$701.68K$855.68KUnavailableUnavailable
Current liabilities$1.46M$983.47K$4.62M$906.33K$1.53M$983.08K$578.94K$704.16KUnavailable$881.41K
Total equity incl. NCI$13.06M$15.80M$19.27M$7.89M$6.63M$5.34M$6.93M$4.23MUnavailable$2.77M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$243.97K
Accounts receivable$3.30M$4.19M$7.81M$168.03K$87.45K$56.47K$84.09K$109.60KUnavailable$40.05K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Edesa Biotech, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-06-302019-03-31
Operating cash flow-$355.32K-$3.12M-$7.18M-$3.01M-$1.67M-$1.35M-$1.17M-$789.71KUnavailable-$398.88K
Capital expenditures-$1.46K$3.51K$2.96K$1.14K$4.03K$0$825$0Unavailable-$4.16K
Investing cash flow$1.46K-$3.51K-$2.96K-$1.14K$3.54K-$26.83K$519.65K-$477.29KUnavailable-$1.50K
Financing cash flow$221.04K$15.91K$11.94M$1.99M$3.23M-$27.49K$3.85M$45.00KUnavailable$0
Net change in cash-$213.32K-$2.91M$4.66M-$908.40K$1.57M-$1.35M$3.16M-$1.20MUnavailable-$324.96K
Stock-based compensation$904.68K$1.10M$467.44K$722.91K$86.39K$11.42K$380.00K$8.78KUnavailable$13.45K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$28.94K$31.21K$29.80K$28.84K$29.02K$23.49K$2.65K$2.40KUnavailable$504

Derived

Edesa Biotech, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-06-302019-03-31
Free cash flowUnavailable-$3.12M-$7.18M-$3.01M-$1.68M-$1.35M-$1.17M-$789.71KUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailable-362.8%98.7%90.9%96.5%UnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailable-402094.8%-1607.9%-1372.0%-1025.7%UnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailable-335393.6%-1230.4%-1059.8%-732.6%UnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable17278.6%Unavailable343.8%8.1%UnavailableUnavailable
Current ratio8.29x14.58x4.64x8.46x5.30x6.33x12.83x6.86xUnavailable9.23x
Revenue YoY growth-100.0%-100.0%-100.0%-100.0%UnavailableUnavailableUnavailableUnavailableUnavailable-100.0%
Net marginUnavailableUnavailableUnavailableUnavailable-402739.6%-1605.5%-1347.9%-1015.2%UnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable230954.2%1040.0%455.0%489.8%UnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable806.2%0.0%0.7%0.0%UnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open EDSA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-Q · Filed 2026-02-13View SEC filing
10-K · Filed 2025-12-12View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

Reconciliation checks needing review

7 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2019-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2019-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2018-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2018-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationreview2020-12-31

Difference 1372213 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2020-09-30

Difference 2476955 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2020-06-30

Difference 2458051 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.